| ¿µ¹® | radiation dose | ÇÑ±Û | ¹æ»ç¼±·® |
|---|---|---|---|
| ¼³¸í | ¹æ»ç¼±Á¶»çÀÇ Á¤µµ. ¹æ»ç¼±»ý¹°ÇÐÀ̳ª ÀÎüÀÇ ¹æ»ç¼±¹æÈ£¿¡¼´Â Àü¸®¹æ»ç¼±ÀÇ ¾ç, Áï ¼±·®ÀÌ ¹®Á¦°¡ µÈ´Ù. ¹æ»ç¼±·®¿¡¼µµ ±¹Á¦´ÜÀ§°è(SI)°¡ ä¿ëµÇ¾î ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)ÀÇ ±Ç°í¿¡ µû¶ó¼ ´ÙÀ½ÀÇ ¿©·¯ ´ÜÀ§°¡ ³Î¸® »ç¿ëµÈ´Ù. ¨ç Èí¼ö¼±·®(absorbed dose). ¹°ÁúÀÇ ´ÜÀ§Áú·®ÀÌ ¹æ»ç¼±¿¡ ÀÇÇØ ¹Þ¾ÆµéÀÌ´Â ¿¡³ÊÁö. ÀÌ ´ÜÀ§´Â ¹æ»ç¼± ¹× ¹°ÁúÀÇ Á¾·ù°¡ ¾î¶°ÇÑ °ÍÀÌ´õ¶óµµ »ç¿ëÇÒ ¼ö ÀÖ´Ù. ±¹Á¦´ÜÀ§´Â J/kgÀ̸ç À̰Ϳ¡ °íÀ¯ÇÑ ¸íĪÀ¸·Î ±×·¹ÀÌ(gray, ±âÈ£ Gy)°¡ ºÎ¿©µÈ´Ù. 1Gy=100¶óµå(rad). ¨è Á¶»ç¼±·®(exposure) ¶Ç´Â °øÁß¼±·®. X¼± ¶Ç´Â ¥ã¼±¿¡ ÇÑÇØ¼ »ç¿ëµÈ´Ù. ±¹Á¦´ÜÀ§´Â C/kg. ¨é ¼±·®´ç·®(dose equivalent). ¹æ»ç¼±¹æÈ£¸¦ À§ÇØ »ç¿ëµÇ´Â ¾ç. ±âÈ£´Â H. H´Â ¹æ»ç¼±ÀÇ Á¾·ù¿Í ¿¡³ÊÁö¿¡ ÀÇÇØ »ýü¿¡ ÁÖ´Â È¿°ú¸¦ º¸Á¤ÇÏ´Â ¼±Áú°è¼ö(Q)¿Í ±× ¹ÛÀÇ ÀÎÀÚ(¿¹¸¦ µé¸é ¼±·®·ü, ¹æ»ç¼ºµ¿À§¿ø¼Ò¿¡ ÀÇÇÑ ³»ºÎÇÇÆø½Ã¿¡´Â ±× ÇÙÁ¾ÀÇ Ã¼³»ºÐÆ÷ µî)¿¡ ±Ù°ÅÇÑ º¸Á¤°è¼ö(N)¸¦ Èí¼ö¼±·®(D)¿¡ °öÇÑ °Í, Áï H=D-Q-N. ¶ÇÇÑ DÀÇ ´ÜÀ§¸¦ Gy ¶Ç´Â rad·Î Ç¥½ÃÇÏ¿´À» ¶§ HÀÇ ´ÜÀ§¸¦ °¢°¢ ½Ãº£¸£Æ®(sievert, ±âÈ£ Sv) ¹× ·½(rem)À̶ó°í ÇÑ´Ù. µû¶ó¼ 1 Sv=102rem. ÀϹÝÀûÀ¸·Î ´ÜÀ§½Ã°£´çÀÇ ¼±·®À» ¼±·®·ü(dose rate)À̶ó°í ÇÑ´Ù. |
||
| ¿µ¹® | dose | ÇÑ±Û | ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·® |
|---|---|---|---|
| ¼³¸í | 1. ¾àÁ¦¸¦ ÇÑ ¹ø ¶Ç´Â ÇÏ·ç¿¡ »ç¿ëÇϰųª º¹¿ëÇÏ´Â ºÐ·®. 2. ¹°ÁúÀ̳ª Á¶Á÷¿¡ ´ëÇÑ ¹æ»ç¼±ÀÇ ÀÛ¿ë Á¤µµ¸¦ ³ªÅ¸³»´Â ¾ç. Áï, ¹æ»ç¼±·®À̶ó´Â °³³äÀº ¾î¶² ÇÑ Á¡¿¡ ÀÔ»çÇÏ´Â ¹æ»ç¼±°ú ±× Á¡ ±Ùó¿¡ ÀÖ´Â ¹°Áú¿¡ ´ëÇÑ ¹æ»ç¼±ÀÇ ¹°¸®Àû-ÈÇÐÀû-»ý¹°ÇÐÀû È¿°ú¿ÍÀÇ °ü°Ô¸¦ Á¤·®ÀûÀ¸·Î ³ªÅ¸³»´Â °øÅëÀΠôµµ·Î¼ »ý°¢µÈ °ÍÀÌ´Ù. ¶óµå(rad)·Î ³ªÅ¸³»´Â Èí¼ö·®, ·»Æ®°Õ(R)À¸·Î ³ªÅ¸³»´Â Á¶»ç ¼±·®, ·½(rem)À¸·Î ³ªÅ¸³»´Â ¼±·® ´ç·®À¸·Î ±¸ºÐÇÏ¿© ¾´´Ù. |
||
| ¿µ¹® | skin dose | ÇÑ±Û | ÇǺμ±·® |
|---|---|---|---|
| ¼³¸í | 1. ÇǺÎÇ¥¸é¿¡¼ÀÇ ¹æ»ç¼±ÀÇ °øÁß¼±·®À¸·Î ¿©±â¿¡´Â 1Â÷¹æ»ç¼±°ú ÈĹæ»ê¶õÀÌ Æ÷ÇԵȴÙ. 2. ÇǺο¡ Èí¼öµÇ´Â ¼±·®. |
||
| ADD | acceptable daily dose; adduction; adenosine deaminase; attentional deficit disorder; average daily d... |
|---|---|
| ID | identification; iditol dehydrogenase; immunodeficiency; immunodiffusion; immunoglobulin deficiency; ... |
| TD | tabes dorsalis; tardive dyskinesia; T-cell dependent; temporary disability; terminal device; tetanus... |
| MVV | 1) Maximal Voluntary Volume = MBV 2) Maximal V... |
| MBC | male breast cancer; maximal bladder capacity; maximal breathing capacity; metastatic breast cancer; ... |
| ADI | Acceptable Daily Intake |
|---|---|
| M.A.O. | Maximal Acid Output |
| MAP | Maximal Aerobic Power |
| MES | Maximal Electroshock |
| M.E.S. | Maximal Electroshock Seizure |
| maximal dose | <pharmacology> The largest amount of a drug or physical procedure that an adult can take with safety. (05 Mar 2000) |
|---|---|
| acceptable daily intake | <pharmacology> This is an estimate of the amount of a substance in food that can be ingested daily over a lifetime by humans without appreciable health risk. The concept of the acceptable daily intake has been developed principally by who and FAO and is relevant to chemicals such as additives to foods, residues of pesticides and veterinary drugs in foods. Acceptable daily intakes are derived from laboratory toxicity data, and from human experiences of such chemicals when this is available, and incorporate a safety factor. The acceptable daily intake is thus an estimate of the amount of a substance in food that can be ingested over a lifetime by humans without significant risk to health (for contaminants in food and drinking water, tolerable intakes - daily or weekly - are used). See: tolerable daily intake. (15 Jan 1998) |
| acceptable risk | <statistics> This relates to the potential for suffering disease or injury that will be tolerated by an individual, group, or society in exchange for the benefits of using a substance or process that will cause such disease or injury. Acceptability of risk depends on scientific data, social, economic, and political factors, and on the perceived benefits arising from a chemical or process that creates the risk in question. (15 Jan 1998) |
| maximal | The greatest possible, allowable or appreciable, the reverse of minimal. (18 Nov 1997) |
| maximal expiratory flow rate | <chest medicine, physiology> Measurement of rate of airflow during the first liter expired after the first 200 ml have been exhausted during a forced vital capacity determination. Common abbreviations are MEFR, FEF 202-1200, and fef 0.2-1.2. Acronym: MEFR (21 Jun 2000) |
| maximal expiratory flow-volume curve | <chest medicine> Curves depicting maximal expiratory flow in liters/second at each point of lung inflation (expressed in liters or percentage of forced vital capacity) during a forced vital capacity determination. Common abbreviation is mefv. (12 Dec 1998) |
| maximal Histalog test | A test for measurement of maximal production of gastric acidity or anacidity; it is similar to the histamine test, but uses Histalog (betazole hydrochloride), an analogue of histamine. Synonym: maximal Histalog test. (05 Mar 2000) |
| maximal midexpiratory flow rate | Measurement of rate of airflow over the middle half of a forced vital capacity determination (from the 25 percent level to the 75 percent level). Common abbreviations are mmfr and fef 25%-75%. (12 Dec 1998) |
| maximal stimulus | A stimulus strong enough to evoke a maximal response. (05 Mar 2000) |
| maximal voluntary ventilation | Measure of the maximum amount of air that can be breathed in and blown out over a sustained interval such as 15 or 20 seconds. Common abbreviations are mvv and mbc. (12 Dec 1998) |
| point of maximal impulse | The point on the chest wall at which the maximal cardiac impulse is seen and/or felt. (05 Mar 2000) |
| absorbed dose | The amount of energy absorbed per unit mass of irradiated material at the target site; in radiation therapy, the former unit for absorbed dose is the rad; the current (S.I.) unit is the gray. (05 Mar 2000) |
| air dose | The radiation dose, expressed in roentgens, delivered at a point in free air. Synonym: air dose. (05 Mar 2000) |
| bone marrow dose | The cumulative dose to the blood-forming organ from therapeutic or nuclear fallout irradiation; the presumed leukemogenic dose. (05 Mar 2000) |
| booster dose | A dose given at some time after an initial dose to enhance the effect, said usually of antigens for the production of antibodies. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|